相关实验视频

Updated: Jan 12, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在ERBB2-突变性肺腺癌中以内拉提尼布为基础的疗法的有效性:来自2项国际第二阶段研究的结果

Bob T Li¹, Leena Gandhi², Vignesh Ravichandran¹

¹Memorial Sloan Kettering Cancer Center, New York, NY.

Clinical lung cancer

|November 5, 2025

概括

单剂内拉替尼对ERBB2突变肺癌的有效性有限. 与泰姆西罗利斯或特拉斯图祖马布的联合治疗仅在少数患者中提供了持久的反应.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

在2-4%的肺癌中,ERBB2突变是关键驱动因素.
这些突变代表了HER2氨酸激酶抑制剂的潜在标.

研究的目的:

评估单独或联合使用内拉替尼的疗效和安全性,用于晚期ERBB2突变肺癌.

主要方法:

两个2期研究 (PUMA-NER-4201和PUMA-NER-5201) 招募了患有ERBB2突变肺癌的患者.
治疗包括内拉提尼布单一治疗,内拉提尼布与西罗利斯,内拉提尼布与特拉斯图祖马布.

主要成果:

客观反应率各不相同:内拉替尼单独治疗的比例为0-3.8%,内拉替尼加西洛利的比例为14.0%,内拉替尼加特拉斯图祖马布的比例为9.6%.
五名患者获得了具有特定ERBB2突变或融合的持久反应 (≥1年).
与治疗相关的≥3级不良事件在治疗手臂中范围为23.5%至48.1%.

结论:

单剂内拉替尼在ERBB2突变肺癌中表现出有限的活性.
组合疗法没有显著改善整体结果,但在一小部分患者中产生了持久的反应.

关键词:

在ERBB2突变中.不是小细胞肺癌的肺癌.铁氨酸激酶抑制剂铁氨酸激酶抑制剂不常见的突变不常见的突变

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...